Ion Beam Applications SA (IBAB.BR)

IBAB.BR on Brussels Stock Exchange

11.61EUR
28 Jul 2014
Price Change (% chg)

€-0.19 (-1.57%)
Prev Close
€11.80
Open
€11.75
Day's High
€11.86
Day's Low
€11.48
Volume
32,191
Avg. Vol
39,742
52-wk High
€12.84
52-wk Low
€5.67

IBAB.BR

Chart for IBAB.BR

About

Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business... (more)

Overall

Beta: 1.40
Market Cap (Mil.): €332.72
Shares Outstanding (Mil.): 28.20
Dividend: --
Yield (%): --

Financials

  IBAB.BR Industry Sector
P/E (TTM): -- 60.57 36.09
EPS (TTM): -0.15 -- --
ROI: 2.50 6.11 18.19
ROE: -6.56 9.31 19.06
Search Stocks

Belgium's IBA gets U.S. approval for compact cancer treatment centres

BRUSSELS, July 16 - Belgian radiotherapy company IBA said on Wednesday it had gained U.S. approval for a key technology, which it said should spur more interest in its newer, compact cancer treatment centres.

16 Jul 2014

BRIEF-Ion beam applications signs contract to install a 70 mev cyclotron in Russia

* IBA signs contract to install a 70 mev cyclotron for to production of radiopharmaceuticals in Russia

02 Jul 2014

BRIEF-IBA selected to install first proton therapy center at UMCG in Netherlands

* Iba sa : iba selected to install first proton therapy center at umcg in netherlands

20 Jun 2014

UPDATE 1-Belgium's IBA keeps guidance in spite of slow start to 2014

BRUSSELS, May 14 - Belgian cancer diagnosis and therapy company Ion Beam Applications maintained its revenue outlook for 2014 on Wednesday even though sales in the first three months came in below target.

14 May 2014

Iba keeps guidance in spite of slow start to 2014

BRUSSELS, May 14 - Belgian cancer diagnosis and therapy company Ion Beam Applications maintained its revenue outlook for 2014 even though sales in the first three months came in below target.

14 May 2014

BRIEF-IBA posts Q1 revenue of 46.3 mln euros; reiterates FY guidance

* Revenues of 46.3 mln euros, up 4 pct compared to same period in 2013

14 May 2014

Belgium's IBA forecasts 2014 revenue growth of 5-10 pct

BRUSSELS, March 26 - Proton therapy group IBA on Wednesday said it expected revenues to grow by between 5 and 10 percent in 2014, driven by demand for its new products.

26 Mar 2014

BRIEF-IBA sees top line growth of 5-10 pct in 2014

BRUSSELS, March 26 - Ion Beam Applications SA : * Combination of Dosimetry and Service revenues grew to 42 pct of total group revenues in 2013 * For 2014 confirmed: 5-10 pct top line growth with 10 pct operating profit * Top line impacted by FX and slowdown in US radiotherapy market for dosimetry, low conversion rate of PT projects * Reported net profit before technical recycling of currency translation adjustment to income statement reached 6.1 mln euros * We entered 2014 with a

26 Mar 2014

BRIEF- IBA signs final contract with Westdeutsches Protonentherapiezentrum Essen

BRUSSELS, March 26 - Ion Beam Applications SA : * Says IBA signs final contract with westdeutsches protonentherapiezentrum Essen * Finalizes the acquisition of the proton therapy center in Essen from Striba Protonentherapiezentrum GMBH * No additional p&l effects beyond what was stated in co's 2013 first half

26 Mar 2014

BRIEF- IBA to divest PharmaLogic PET Services of Montreal company assets

BRUSSELS, March 17 - Ion Beam Applications SA : * Says IBA closes agreement to divest PharmaLogic pet services of Montreal company assets * About 85 percent of price has been paid to PharmaLogic at closing and rest will be released after a two year period * Says payments will then be distributed as dividends to PharmaLogic's shareholders, including IBA * Says expects a net total cash inflow in dividend from this sale of about EUR 7.7 million * Deal will have no impact on 2013 acc

17 Mar 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks